Indications for different types of plasma in hematological diseases;Indications des différents types de plasma dans les maladies hématologiques

Hematologie

Volumn 15, Issue 5, 2009, Pages 356-363

  Schneider, Thierry ^a   Hacquard, Marie ^a,b   Lecompte, Thomas ^b,c,d  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Amotosalen ultraviolet light treated plasma; Fresh frozen plasma; Methylene blue light treated plasma; Solvent detergent treated plasma; Thrombotic thrombocytopenic purpura; Transfusion

Indexed keywords

AMOTOSALEN; DETERGENT; FRESH FROZEN PLASMA; METHYLENE BLUE; PLASMA SUBSTITUTE;

ALLERGY; DEGRADATION; FRANCE; HEMATOLOGIC DISEASE; HEMOSTASIS; MICROANGIOPATHY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SENSITIZATION; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULTRAVIOLET RADIATION; VIRUS;

EID: 71949106453     PISSN: 12647527     EISSN: 19506368     Source Type: Journal    
DOI: 10.1684/hma.2009.0381     Document Type: Review

References (50)

1. Ministère de La Santé. Arrête du 3 décembre 1991 relatif à l'utilisation du plasma congelé. Journal Officiel 1991, 12 décembre: 16217.
2. Agence Française de Sécurite Sanitaire des Produits de Santé. Transfusion de plasma frais congelé: produits, indications. Paris, Afssaps, août 2002.
3. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DBL, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-152
4. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. British society of haematology. Br J Haematol 2003; 120: 556-573
5. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
6. Evan Sadler JJ. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-17
7. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35. (Pubitemid 46239348)
8. Schleinitz N, Poullin P, Camoin L, et al. Le purpura thrombotique thrombocytopénique acquis de l'adulte: actualités. La revue de médecine interne 2008; 29: 794-800.
9. Fenaux P, Chastang C, Chevret S, Sanz MA. A randomized comparaison of ATRA followed by chemotherapy ans ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed anti-promyelocytic leukaemia. Blood 1999; 54: 1192-1200 (Pubitemid 29380399)
10. Pillonel J, Laperche S. Surveillance épidémiologique des donneurs de sang homologues et risque résiduel en France entre 2003 et 2005. BEH 2006: 51-52
11. Rapport d'activités d'hémovigilance. Pôle Vigilances. Direction médicale et scientifique. Établissement français du sang, Saint-Denis, 2006, 2007, 2008.
12. Dodd RY. Emerging transfusion transmitted infections: species barriers and the risks for transfusion medicine. ISBT Science Series 2008; 3: 71-76
13. Alter J. Pathogen reduction: a precautionary principle paradigm. Tranfus Med Rev 2008; 22: 97-102.
14. Horowitz B, Wiebe M, Lippin A, Stryker MH. Inactivation of virus in labile blood products. Description of lipid enveloped virus by tri n-butyl phosphate detergent combination. Transfusion 1985; 25: 216-219
15. Horowitz B, Lozo A, Page G, Lippin A, Swang G. Virus inactivation by solvant/detergent and the manufacture of SD-plasma. Vox Sang 1998; 74 (Suppl. 1): 203-206
16. Fiche produit du plasma viro-atténué par solvant détergent. Établissement français du sang, Saint-Denis, 2008.
17. Pamphilon D. Viral inactivation of fresh frozen plasma. Br J Haematol 2000; 109: 680-693 (Pubitemid 30609743)
18. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best practice and research Clinical Haematology 2006; 19: 205-242
19. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207-213
20. Seghatchian J, Walker W, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Tranfus Apheresis Sci 2008; 38: 271-280
21. Fiche produit du plasma viro-atténué par le bleu de méthylène. Établissement français du sang, Saint-Denis, 2008.
22. Williamson L, Cardigan R, Prowse C. Methylene blue-treated fresh-frozen plasma: what is contribution to blood safety? Transfusion 2003; 43: 1322-1329
23. Abe H, Yamada-Ohnishi Y, Hirayama J, Owada T, Ikeda H, Ikebuchi K. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system. Transfusion 2000; 40: 1081-1087 (Pubitemid 30688719)
24. Knuver-Hopf J, Mohr H. Parvovirus B19 is sensitive to photodynamic and photochemical treatment. Abstract book VII European congress of the ISBT 2003: 94.
25. Gironés N, Bueno JL, Carrion J, Fresno M, Castro E. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006; 91: 285-291 (Pubitemid 44720162)
26. Singh Y, Sawyer L, Pinkoski L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-1177 (Pubitemid 44139491)
27. Horowitz B. Pathogen inactivated transfusion plasma: existing and emerging methods. Vox Sang 2002; 83 (Suppl. 1): 429-436
28. e Congrès national de la SFTS, 2-5 juillet 2007, Tours).
29. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thrombosis Research 2002; 107: S3-8.
30. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apheresis Sci 2006; 35: 83-90. (Pubitemid 44354323)
31. Schlenke P, Hervig T, Isola H, et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008; 48: 697-705.
32. Hemker HC, Giesen P, Aldieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15. (Pubitemid 37449290)
33. Cardigan R, Philpot K, Cookson P, Luddington R. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009; 49: 696-703.
34. Isbister JP. Adverse reactions to plasma and plasma components. Anaesth Intens Care 1993; 21: 31-38
35. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years'experience. Vox Sang 2007: 1-8.
36. Rapport annuel d'hémovigilance en Belgique. Agence fédérale des médicaments et des produits de santé. Bruxelles: AFM PS, 2006, 2007.
37. Dewatcher P, Mouton-Faivre C, Tréchot P, Lleu JC, Mertes PM. Severe anaphylactic shock with metylene blue instillation. Anesth Analg 2005; 101: 149-150 (Pubitemid 40853366)
38. Rodrigues JM, Filho A, Rodrigues AJ, De Andrade Vincente WV, Evora PR. Methylene blue for clinical anaphylaxis treatment: a case report. Sao Paulo Med J 2007; 125: 60-62 (Pubitemid 46813350)
39. Coignard BP, Nguyen GT, Tokars JI. A cluster of intra operative? death in a liver transplant center associated with the use of solvent/detergent plasma. Abstract, SHEA 11th annual meeting. Mt Royal: Society for healthcare epidemiologie of America, 2001.
40. Carte de soins et d'urgence en cas de déficit en Glucose-6-Phosphate Déshydrogénase. Ministère de la santé et des solidarités. Paris: Direction générale de la santé, 2008.
41. Médicaments et déficit en Glucose-6-Phosphate Déshydrogénase. Agence française de sécurité sanitaire des produits de santé. Paris: Afssaps, février 2008.
42. Inbal A, Epstein O, Blickstein D, Kornbrot D, Brenner B, Martinowitz V. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood coagulation and Fibrinolysis 1993; 4: 599-604. (Pubitemid 23236583)
43. Horowitz MS, Petha JC. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74: 231-235
44. Pohl U, Wieding JU, Kirchmaier CM, et al. Treatment of patients with severe congenital coagulation factor V or XI deficiency with methylene blue virus inactivated fresh frozen plasma (MB-VIP). Abstract ISBT, Fifth regional Congress, Venezia, 1995: 93.
45. Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factors deficiencies. Transfusion 2005; 45: 1362-1372 (Pubitemid 41647805)
46. Evans G, Lewelyn C, Luddington R, Baglin TP, Williamson LM. Solvant/detergent fresh frozen plasma a primary treatment of acute thrombotic thrombocytopenic purpura. Clinical and laboratory haematology 1999; 21: 119-123 (Pubitemid 29234339)
47. Rio-Garma J, Alvarez-Larran A, Martinez C, et al. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
48. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48: 108-117
49. Rio-Garma J, Pereira A, Arroyo JL, et al. ADAMTS13 activity and Von Willebrand factor levels in methylene blue photo-inactivated plasma processed by either the Springe method or an "in house" system. Vox Sang 2008; 95: 101-105
50. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693-1704 (Pubitemid 44435721)